Table 4A. Median visual acuity and eyes retaining hand motions or greater vision after NVG diagnosis.

	Bevacizumab group (n=64)	Non-bevacizumab group (n=99)	P-value
1 month
Median (range)	CF (20/30, LP)	CF (20/30, NLP)	0.38a
N (%)	48 (44)	61 (56)	0.23b
3 months
Median (range)	2/200 (20/20, NLP)	HM (20/30, NLP)	0.28a
N (%)	40 (46)	48 (55)	0.013b
6 months
Median (range)	3/250 (20/50, NLP)	HM (20/25, NLP)	0.48a
N (%)	27 (47)	31 (53)	0.79b
12 months
Median (range)	CF (20/30, NLP)	CF (20/30, NLP)	0.93a
N (%)	15 (35)	28 (65)	0.48b

Abbreviations: CF, count fingers; HM, hand motion; NLP, no light perception.

^aTwo-sample Wilcoxon test.

^bFisher exact test.